

OraSure, Thermo Fisher agreement, 2/14

February 2014—OraSure Technologies has reached an agreement with Thermo Fisher Scientific to develop and supply up to 12 homogenous, fully automated oral fluid drugs-of-abuse assays to be used with OraSure's new Intercept oral fluid specimen collection device. OraSure will have the right to purchase and resell the assays in the U.S. and certain foreign countries, subject to receipt of applicable regulatory approvals.

Under the agreement, a NIDA-5 panel of assays is expected to be sold with the next-generation Intercept device in the domestic criminal justice and forensics markets beginning in the second half of 2014. The parties expect to complete development of several more assays and obtain FDA 510(k) clearance and approvals in certain foreign countries. The assays will be optimized as needed to comply with new oral fluid guidelines expected to be issued by the Substance Abuse and Mental Health Services Administration.

[***OraSure Technologies***](#), 918-748-4006